IRMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
IRADIMED CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$87.65−0.62 (-0.70%)
Close on Oct 19, 2026
- Market cap
- $1.13B
- P/E (TTM)
- 49.0
- Dividend yield
- –
IRADIMED CORP revenue by segment
By business segment
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $71.16M | $72.63M | $70.56M | $68.76M | $65.86M | $63.15M | $60.61M | $57.75M | $56.49M | $53.96M | $52.53M | $51.17M | 82.4% | +8.1% |
| International | $15.18M | $13.65M | $13.26M | $11.75M | $11.78M | – | $12.64M | – | – | – | – | – | 17.6% | +28.9% |
| International | – | – | – | – | $11.78M | $12.00M | $12.64M | $13.55M | $12.99M | $13.73M | $13.04M | $11.80M | – | – |
From the segment and revenue-disaggregation notes of Iradimed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.